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Abstract 
This study investigated the risk factors to the outbreak of Ebola Bundibugyo in Bundibugyo district. The 
research aimed at investigating the different risk factors that led to the outbreak of Ebola Bundibugyo Virus 
(BDBV) in Bundibugyo district. The study adopted a cross-sectional survey that provided a baseline data on the 
cultural risk factors which influenced the outbreak, distribution, intensity and the spreading of BDBV among the 
communities of Bundibugyo district. 56 cases were confirmed with 40% fatality. The cultural risk factors 
investigated were taming wild animals, hunting, burying the dead, washing the dead bodies and sleeping near the 
dead bodies. 
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Introduction 
Ebola virus is part of the filoviridae family with Marburg. Ebola, named after Ebola River found in former Zaire, 
now called DRC in 1976 was first confirmed in Sudan and Zaire. Ebola is believed to be zoonotic; however the 
natural reservoir is unknown, despite extensive investigations. Non-human primates have been identified as a 
source of human infection; surprisingly they are not thought to be the reservoir as they develop severe, fatal 
illness when infected ( WHO,2015).  
High numbers of animal carcasses were noted in surrounding areas prior to outbreaks in Gabon and DRC, 
and recovered carcasses were infected with a variety of strains of Ebola virus suggesting they were not the 
reservoir but had been infected by more than one source(WHO,2016). 
Harvesting of migrating fruit bats was thought to be the source of a large outbreak in the DRC in 2007 
(DCD,2007-2016) 
The first out-break was first confirmed in Sudan, called Ebola-Sudan. 284 people were affected with a 
mortality rate of 53%. A second out-break was confirmed in Yambuku Zaire called Ebola Zaire, affecting over 
318 people with a mortality rate of 88% in just two Months of the out-break. (Tara, 1999). 
There are five (5) species of Ebola virus, four (4) of which have caused diseases in humans: 
Zaïre ebolavirus (EBOV) 
Sudan ebolavirus (SUDV) 
Tai Forest (TAFV) (formerly known as Ebola Ivory Coast) 
Bundibugyo ebolavirus (BDBV) 
Dedicated research shows the first strain of Ebola (Ebola Reston) in Monkeys imported to Reston in 1989. Other 
outbreaks are; Ebola Gulu and Bundibugyo in Uganda and the most recent and fatal in West Africa. (Miranda et 
al.2002). 
The 2013-15 Ebola outbreaks in Western Africa is far the largest recorded and wide spread of this disease 
to date, with the highest case numbers exceeding the total numbers from the previous out breaks (Julii et al.,2015) 
Furthermore, data shows that the first human case in an Ebola outbreak was acquired through contact with 
blood, secretions organs or other bodily fluids of an infected animal. EVD has been documented in people who 
handled infected chimpanzees, gorillas and forest antelopes, both dead and alive, in Cote d’Ivoire, the Republic 
of Congo and Gabon. The first case in the West Africa outbreak was likely acquired via exposure to bats. The 
virus is then transmitted from person to person through direct contact with the blood, secretions, organs or other 
bodily fluids of infected persons. People can also become infected through contact with objects, such as needles 
or soiled clothing, that have been contaminated with infected secretions ( Duchene et al., 2014) 
Outbreaks have been fuelled by traditional burial practices, in which mourners have direct contact with the 
bodies of the deceased. Acquisition via sexual contact with a convalescent case or survivor is possible as the 
virus can be present in semen for many months after recovery. Hunting apes and destroying their habitat are 
evidently contributing to the outbreaks. Despite these and more facts, it is readily apparent that Ebola has 
continued to pose a serious threat to the health of humans and apes alike (Kate, 2015) 
Current out-breaks in Africa have showed a link between areas of wildlife conservation and human 
interaction with wildlife and have created a serious conflicts between human communities and Apes populations. 
A number of risk factors were identified in Ebola Bundibuigyo; like traditional practices like washing the dead, 
burying the dead, sleeping near the dead among others, However, others risk factor remained unidentified 
(Drummond et. al.,2012). 
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Conclusion 
Findings of this research indicated that cultural risk factors were significantly related to the general 
epidemiology of Ebola virus in Bundibugyo district.  
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